• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can Chemours (CC) Look Undervalued After Its PFAS Settlement?

    Simply Wall St·06/25/2026 07:21:22
    Listen to the news

    Why the Chemours settlement matters for stockholders

    Chemours (CC) has agreed to a multi-state settlement with the US Department of Justice and the EPA over PFAS related environmental claims, committing to civil penalties and long term mitigation and pollution control projects.

    The agreement addresses alleged PFAS emissions at several Chemours facilities and includes expanded drinking water and remediation programs in affected communities. It also increases the company’s environmental reserves and future compliance obligations.

    See our latest analysis for Chemours.

    Chemours’ settlement news arrives after a mixed price pattern, with the share price return up 72.82% year to date but the 3 year total shareholder return down 33.34%. This suggests momentum has recently improved while longer term holders have experienced weaker results.

    If this kind of risk and reward trade off has your attention, it may be a good moment to see what else is moving in materials and heavy industry via 33 power grid technology and infrastructure stocks

    With Chemours stock up 72.82% year to date, yet still carrying a 62% intrinsic discount estimate and a loss of $410 million, should you view this settlement reset as a mispriced opening or as a market already banking on better days?

    Most Popular Chemours Narrative: 19.6% Undervalued

    Chemours is trading at $21.17 against a narrative fair value of $26.33, so the most followed view sees meaningful upside baked into its long term cash flow story.

    Secular demand growth for advanced materials tied to electrification, renewables, data centers, and energy storage is generating incremental sales in higher-value applications for APM; ongoing portfolio optimization and pricing improvements in these segments are structurally enhancing net margins and improving earnings quality.

    Read the complete narrative.

    Want to see how that margin story underpins the fair value gap? The narrative leans on a sharp swing in profitability, a richer mix, and a compressed earnings multiple.

    Result: Fair Value of $26.33 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Chemours still faces meaningful risks, including unresolved PFAS liabilities and potential pressure on refrigerant pricing if regulatory shifts reduce demand for newer products.

    Find out about the key risks to this Chemours narrative.

    Next Steps

    Does this Chemours story strike you as cautiously optimistic or still unresolved? Act while the data is fresh and pressure test both sides by reviewing the 4 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Chemours?

    If Chemours has sharpened your focus on risk, value, and timing, do not stop here. Broaden your watchlist and pressure test fresh ideas while conditions still favor careful stock picking.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.